Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab Phase 3 in Systemic Sclerosis
NCT03957681Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic sclerosis (SSc) comparing KHK4827 with Placebo (2 arms). Primary endpoint: Change in modified Rodnan skin score (mRSS) from baseline at Week 24. Started May 2019; status: completed.
02
Drugs
brodalumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT03957681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957681.